Dynavax Technologies Corporation (DVAX)

Cash ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cash and cash equivalents	US$ in thousands	150,279	154,511	226,823	174,350	202,004	198,576	249,091	179,421	436,189	246,351	129,608	79,055	32,073	32,688	60,485	37,899	39,884	37,297	34,225	112,133
Short-term investments	US$ in thousands	592,023	565,905	454,702	477,606	422,391	387,910	269,078	323,795	109,811	167,849	216,192	153,645	132,927	144,512	140,215	91,601	111,216	137,603	106,275	71,067
Total current liabilities	US$ in thousands	62,195	54,264	44,862	91,515	150,074	244,080	345,198	466,203	556,402	528,935	204,642	109,422	77,411	66,625	53,222	29,279	53,047	46,348	44,573	42,251
Cash ratio		11.94	13.28	15.19	7.12	4.16	2.40	1.50	1.08	0.98	0.78	1.69	2.13	2.13	2.66	3.77	4.42	2.85	3.77	3.15	4.34

December 31, 2023 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($150,279K + $592,023K) ÷ $62,195K
= 11.94

The cash ratio of Dynavax Technologies Corp. has shown an increasing trend over the past eight quarters, indicating a strengthening liquidity position. The ratio has improved from 1.55 in Q1 2022 to 12.24 in Q4 2023. This suggests that the company's ability to meet its short-term obligations using cash and cash equivalents has significantly improved over this period. The latest cash ratio of 12.24 means that the company has $12.24 of cash and cash equivalents for every dollar of current liabilities, demonstrating a healthy liquidity position in the most recent quarter. Overall, the upward trend in the cash ratio reflects positively on the company's financial health and its ability to manage short-term liquidity risks effectively.